MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
132.16
-0.31
-0.23%
After Hours: 132.00 -0.16 -0.12% 19:53 10/05 EDT
OPEN
132.50
PREV CLOSE
132.47
HIGH
133.27
LOW
129.51
VOLUME
142.88K
TURNOVER
--
52 WEEK HIGH
161.38
52 WEEK LOW
65.93
MARKET CAP
1.90B
P/E (TTM)
-27.3935
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PVLA last week (0928-1002)?
Weekly Report · 21h ago
Palvella Therapeutics is Now Oversold (PVLA)
NASDAQ · 3d ago
Palvella Therapeutics: FDA Handholding Makes The Regulatory Story Stronger
Seeking Alpha · 6d ago
Palvella receives third year of grant funding from FDA for QTORIN
TipRanks · 09/28 11:50
Palvella Receives Additional FDA Funding For QTORIN Rapamycin In Lymphatic Malformations
NASDAQ · 09/28 11:48
Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic Malformations
Benzinga · 09/28 11:35
Weekly Report: what happened at PVLA last week (0921-0925)?
Weekly Report · 09/28 09:25
Palvella Therapeutics Is Maintained at Buy by Chardan Capital
Dow Jones · 09/21 14:06
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.